Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/650 vs AMOXAPINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Major depressive disorder,Anxiety,Panic disorder,Off-label: neuropathic pain, insomnia
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Parent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Primarily hepatic via CYP2D6 and CYP3A4; major metabolite is 8-hydroxyamoxapine, which is pharmacologically active.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Approximately 80-90%, primarily to albumin and alpha-1-acid glycoprotein
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
0.8-1.2 L/kg, indicating extensive tissue distribution
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Oral: approximately 60-70% due to first-pass metabolism
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use or reduce dose by 75%
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Child-Pugh Class A: start at 25 mg twice daily; Class B: 25 mg once daily; Class C: avoid use
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Not recommended for use in children under 16 years
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Initial dose 25 mg twice daily, increase slowly; maximum 300 mg/day
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Suicidality risk in young adults,Serotonin syndrome when combined with other serotonergic drugs,Extrapyramidal symptoms due to weak D2 blockade,Seizure risk,Cardiotoxicity (prolonged QT interval) at high doses,Agranulocytosis (rare)
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Hypersensitivity to amoxapine or any dibenzoxazepine,Concomitant use with MAOIs (including linezolid and methylene blue),Recent myocardial infarction,Uncontrolled narrow-angle glaucoma,Urinary retention,QT prolongation or concurrent use of drugs that prolong QT
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Avoid alcohol and beverages with high tyramine content (e.g., aged cheese, cured meats, fermented foods) only if patient is also on MAOIs; not a specific requirement for amoxapine alone. Grapefruit juice may inhibit metabolism; advise caution or avoid large amounts. For patients with hypertension or seizure disorders, avoid excessive caffeine.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
First trimester: Limited data; risk of neural tube defects? Second trimester: No specific associations. Third trimester: Risk of neonatal withdrawal (irritability, feeding difficulties). Overall: FDA Category C; avoid in first trimester if possible.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Excreted in breast milk; M/P ratio not established. Use caution due to potential for infant sedation and anticholinergic effects; monitor for drowsiness and poor feeding.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
No established dose adjustments; increased clearance in pregnancy may require dose increase to maintain efficacy; monitor therapeutic response and serum levels if available.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Amoxapine is a dibenzoxazepine antidepressant with both tricyclic-like reuptake inhibition and dopamine receptor blocking properties. Monitor for extrapyramidal symptoms (EPS) and tardive dyskinesia, especially in elderly. Due to dopamine blockade, it may cause hyperprolactinemia. For patients with seizures, use cautiously; dose-dependent seizure risk is higher than with other TCAs. Onset of antidepressant effect may be 2-4 weeks. Use lower initial doses in elderly and hepatic impairment. Avoid in recent myocardial infarction.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
Take exactly as prescribed; do not increase or stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the medication affects you.,Avoid alcohol and other CNS depressants.,Report any muscle stiffness, tremor, restlessness, or unusual movements of the face or tongue.,Notify your doctor if you experience rapid or irregular heartbeat, difficulty urinating, or blurred vision.,May cause dry mouth; use sugarless candy or gum and maintain good oral hygiene.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take any other medications, including over-the-counter products, without approval from your healthcare provider.
No interactions on record
"Combined use of Oxprenolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, and Amoxapine, a tricyclic antidepressant, may lead to additive cardiovascular adverse effects. Amoxapine can inhibit the metabolism of beta-blockers via competition for CYP450 enzymes, increasing oxprenolol plasma concentrations. This interaction heightens the risk of bradycardia, hypotension, and may precipitate heart block or arrhythmias, particularly in patients with pre-existing cardiac disease."
"The combination of amoxapine, a tricyclic antidepressant with strong anticholinergic properties, and clidinium, a quaternary ammonium anticholinergic used for gastrointestinal spasms, results in additive anticholinergic effects. This can lead to excessive peripheral and central anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, tachycardia, cognitive impairment, and exacerbation of glaucoma or paralytic ileus. In severe cases, anticholinergic toxicity may manifest as hyperthermia, delirium, or seizures, particularly in elderly patients or those with pre-existing conditions."
"Telavancin, a lipoglycopeptide antibiotic, prolongs the QT interval by inhibiting the delayed rectifier potassium current (IKr) in cardiac myocytes. Amoxapine, a tricyclic antidepressant, also blocks cardiac sodium and potassium channels, leading to dose-dependent QTc prolongation. Concomitant use increases the risk of torsade de pointes, ventricular arrhythmias, and sudden cardiac death, particularly in patients with electrolyte imbalances, bradycardia, or preexisting QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/650 vs AMOXAPINE, answered by our medical review team.
ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. AMOXAPINE is a Tricyclic Antidepressant that works by Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/650 and AMOXAPINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. The standard adult dose of AMOXAPINE is: 200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/650 and AMOXAPINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . AMOXAPINE is classified as Category C. First trimester: Limited data; risk of neural tube defects? Second trimester: No specific associations. Third trimester: Risk of neonatal withdrawal (irritability, feeding difficul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.